Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Margetuximab vs Trastuzumab in Chinese Patients with Advanced HER2+ Breast Cancer
NCT04262804Phase 2Unknown
- Sponsor
- Zai Lab
- Start
- Jan 2020
- Primary completion
- Sep 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of margetuximab in HER2-positive metastatic breast cancer, sponsored by Zai Lab. Status: unknown.
02
Drugs
margetuximab
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT04262804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262804.